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Purpose: To evaluate the initial clinical experience of computed tomography (CT) imaging-guided percu-
taneous cryotherapy of bladder cancer.
Patients and methods: This study was approved by the human subjects committee. Written informed con-
sent was obtained from all patients. Thirty-two patients (22 males and 10 females; mean age, 62.7 years)
with muscle-invasive bladder cancer were treated with CT imaging-guided percutaneous cryoablation.
By using CT imaging system and local anesthesia in patients, a single or multiple 1.47 mm cryoprobes
were used to freeze the target bladder tumor (mean tumor size, 2.8 cm; range, 1.3–4.5 cm) with a dual
freeze–thaw cycle. Follow-up was performed to assess the clinical and technical outcome of patients
treated with cryoablation for a minimum of 6 months (mean, 33 months; range, 6–48 months). Tumors
were considered completely ablated if there was no evidence to suggest tumor enhancement at follow-up
CT images.
Results: Bladder cryoablation was clinically and technically successful in all 32 cases, 30 of which
required only one treatment session. Bladder integrity was maintained in all patients. Major complica-
tions were not observed in any patient.
Conclusion: Our initial experience of a minimally invasive method for ablating bladder tumors with CT
imaging-guided percutaneous argon–helium cryoablation appears to be favorable, with acceptable oper-
ative and short-term clinical outcomes. The technique is safe and effective for the treatment of patients
with muscle-invasive bladder cancer; however, long-term follow-up is needed.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Bladder cancer is a relatively common malignant cancer in the
urinary system, and shows an increasing tendency in Asia [15].
About 15 cases of bladder cancer occur per 100,000 persons world-
wide and 0.13 million persons die of bladder cancer annually [23].
Although radical cystectomy and urinary diversion has been the
gold standard of care for invasive bladder cancer, the technique is
associated with signiﬁcant morbidity and functional compromise
[16]. Because of the perioperative morbidity and postoperative
complications of radical cystectomy, many bladder-sparing options
have been adopted for bladder cancer, including partial cystectomy,
transurethral resection of bladder tumor (TURBT), chemotherapy,and/or radiation [9,5]. Imaging-guided percutaneous ablativemeth-
ods have been proposed as an alternative to partial tumor excision,
such as partial nephrectomy [13]. Methods such as using computed
tomography (CT)- or magnetic resonance imaging (MRI)-guided
radiofrequency ablation and cryoablation can be performed percu-
taneously, and are likely to play an important role in the treatment
of multiple tumors.
Cryoablation is a well-characterized and understood ablation
technology that has been applied clinically to treat both benign
and malignant disease in many different organs, such as the kid-
ney, pancreas, prostate gland, adrenal gland, lung, and liver
[8,7,4]. Argon–helium cryoablation is a new local ablation tech-
nique based on in situ freezing and devitalization of tissues. This
technology caused some authors to question its use in cancers,
with consideration of a theoretical risk of post-procedure hemor-
rhage [24]. However, there has some evidence to suggest that there
is no signiﬁcant difference in the rate of hemorrhage following
L. Sun et al. / Cryobiology 69 (2014) 318–322 319radiofrequency ablation versus cryoablation [19]. Following the
gradual downsizing of cryoprobes, percutaneous argon–helium
cryoablation has been feasible, and offers several advantages ver-
sus other approaches. First, the ablation zone of the percutaneous
cryoablation approach can be carefully monitored and visualised
using CT or MRI. Second, the percutaneous approach is less inva-
sive and relatively painless compared with other procedures, such
as laparotomic methods and heat-based ablation modalities [14].
A large body of evidence has suggested that imaging-guided
percutaneous cryoablation is safe and effective for many cancers,
such as liver tumors and renal tumors [20,21,25]. On the basis of
the effectiveness and safety beneﬁts of percutaneous cryoablation,
and the advantages of CT in monitoring cancerous tissues effects of
freezing, we treated patients’ bladder tumors with CT imaging-
guided percutaneous argon–helium cryoablation. In this investiga-
tion, we document our experience of percutaneous cryoablation for
bladder cancer in 32 patients. The goal of the current study was to
examine the safety and efﬁcacy of CT imaging-guided percutane-
ous argon–helium cryoablation of bladder cancer.Patients and methods
A total of 32 patients with bladder cancer who were treated for
bladder cancer at the Radiology Department, Xijing Hospital,
Fourth Military Medical University between April 2003 and June
2010 were included in this study. Bladder cancer was diagnosed
based on imaging ﬁndings and conﬁrmed by cystoscopy. Clinical
staging was based on the tumor-node-metastasis (TNM) classiﬁca-Table 1
Descriptive statistics of bladder cryoablation patients treated on protocol.
No. Gender/
Age
Mass size (cm) Clinical
stage
Pathology
classiﬁcation
Preope-
rative
Intraope-
rative
1 M/52 1.3 1.5 T2a G2
2 M/79 4.2 4.4 T4 G3
3 F/55 4.5 4.4 T4 G3
4 M/61 1.4 1.7 T2b G1
5 M/60 1.4 1.3 T2a G2
6 M/53 3.1 3.0 T3 G3
7 F/63 1.6 1.8 T2a G2
8 M/64 3.2 3.0 T3 G3
9 M/72 3.5 3.6 T3 G3
10 F/57 4.0 3.9 T3 G3
11 M/68 3.9 4.2 T4 G3
12 M/66 1.8 2.1 T2b G2
13 M/61 2.3 2.2 T3 G1
14 M/59 2.5 2.6 T3 G1
15 F/60 2.7 2.6 T3 G2
16 M/73 3.3 3.5 T3 G1
17 M/64 1.6 1.8 T2b G1
18 F/66 2.2 2.4 T3 G2
19 M/58 2.8 3.0 T3 G3
20 M/74 3.7 3.5 T3 G3
21 M/60 4.3 4.4 T4 G3
22 F/57 4.7 4.4 T4 G2
23 M/55 1.6 1.5 T2b G1
24 M/69 2.9 2.7 T3 G3
25 F/72 3.7 3.8 T3 G2
26 M/65 3.1 3.3 T3 G3
27 F/56 4.4 4.4 T4 G3
28 M/76 3.0 3.1 T3 G2
29 F/58 1.5 1.6 T2a G1
30 M/53 1.4 1.6 T2b G1
31 F/52 2.7 2.8 T3 G2
32 M/67 2.3 2.1 T3 G2
Mean 62.7 2.8 2.9 / /
(SD = 7.3) (SD = 1.0) (SD = 1.1)tion; all patients in our study had clinical stage T2-T4aN0M0 blad-
der cancer. The 32 patients had a total of 34 tumors of 1.3–4.7 cm
in diameter (mean size 2.8 cm). The clinical characteristics of the
patients are summarized in Table 1. All protocols in our study were
approved by the Ethics Committee and the human subjects com-
mittee at Xijing Hospital. All patients participating in the study
were Chinese in origin and provided written informed consent
for the treatment.
In accordance with the protocol approved by the human sub-
jects committee at Xijing Hospital, the criterion for the inclusion
of patients in this study was that the subject was an adult with a
metastatic neoplasm of the bladder, including advanced-stage
bladder cancer, ﬁndings on CT that were interpreted as likely to
represent a metastatic bladder tumor, and patients with recur-
rence after surgery. To be included in a study of an innovative ther-
apy, patients should have correctable or normal hemostatic
parameters and no contraindications to CT. The last criterion, but
the most important, was that patients with a tumor of <5 cm in
diameter were to receive cryoablation therapy in the study.
Patients were ineligible for these protocols for several reasons
[18]: distant spread of disease; hydronephrosis; use of other abla-
tive therapies before cryoablation; a tumor of >5 cm in diameter;
patient refusal to sign a consent form to approve the treatment;
and patients with severe irritative bladder symptoms were not
candidates for the bladder-preserving protocols.
Before the surgical procedure, we used the 18F ﬂexible cysto-
scope working channel (CYF-2, Olympus Keymed, UK) to examine
the location and number of tumors. Patients with larger tumors
were examined by cystography. A preprocedural dual-source CTComplications
Before cryosurgery After cryosurgery
Hematuria Hematuria
Hematuria, urinary irritation Hematuria
Abdominal pain Hematuria
Hematuria, lumbago Hematuria
Hematuria
Hematuria Abdominal pain
Abdominal pain
Hematuria, urinary irritation Urinary irritation
Hematuria, urinary irritation Hematuria
Hematuria Hematuria
Urinary irritation
Hematuria Hematuria
Hematuria Hematuria
Hematuria, lumbago Abdominal pain
Abdominal pain
Hematuria, abdominal pain
Hematuria, urinary irritation, abdominal
pain
Hematuria, urinary
irritation
Abdominal pain Abdominal pain
Lumbago
Hematuria, abdominal pain Abdominal pain
Hematuria
Hematuria, abdominal pain Hematuria
Hematuria Hematuria
Lumbago
Hematuria, abdominal pain
Hematuria Lumbago
Hematuria, abdominal pain Abdominal pain
/ /
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Germany) was employed to assist in the planning of the CT-guided
cryoablation treatment and to serve as the baselinewithwhich pos-
tablation CT could be compared. An oral contrast agent in CT imag-
ing was administrated for all patients with bladder cancer, and a
three-cavity indwelling catheterwas inserted in patients before sur-
gery. Intraoperatively, an intravenous contrast agent for bladder
was administered, and the bladder was irrigated with warm water.
A catheter was inserted in patients 2–4 weeks after cryoablation.
Percutaneous cryotherapy was performed using a cryoablation
system (Cryo-hit, Galil Medical, Israel; employing argon/helium
gases using 1.47 mm needles), including as many as 25 cryoprobes
(Fig 1). Interventional guidance and monitoring for cryotherapy
were performed using a CT system scanner. All 32 patients under-
went argon–helium cryoablation during a single procedure, expect
for two who were re-treated. Procedures were performed after
induction of local anesthesia in the patients. All 34 tumors were
treated by an argon/helium gases-based Cryo-hit system and
cryoprobes. According to the size and position of the tumor, a sin-
gle or multiple 1.47 mm cryoprobes were used to freeze the target
bladder tumor with a dual freeze–thaw cycle (10-min freeze, 5-
min thaw) under CT guidance. In general, one cryoprobe generates
an ice ball that is 3 cm in diameter and 5 cm in length along the
probe shaft [3].The iceball’s dimensions were monitored via intra-
operative CT. The rapid expansion of argon gas in a sealed cryo-
probe with a distal uninsulated portion resulted in rapid freezing
of tumor tissue, and cryoprobe tip temperatures reached a nadir
of approximately 140 C within seconds. Thawing was accom-
plished by replacing the argon gas with helium gas. Tumor freezing
was monitored; if the ice ball did not encompass the tumor
entirely, additional cryoprobes were placed.
CT imaging was performed 24 h after cryoablation to document
technical success, assessment of complications, such as bleeding or
urinary ﬁstula formation, and provide a baseline for future follow-
up imaging and pretreatment CT. Follow-up images with CT were
obtained at 3, 6, 12, 18, 24, 36 and 48 months after cryoablation.
Tumors were considered completely ablated if there was no evi-
dence to suggest tumor enhancement by intravenous contrast
material [3].Fig. 1. (A) The computed tomography (CT) imaging-compatible argon–helium cryoabl
1.47 mm needles). (B) CT imaging-compatible 1.47 mm diameter cryoprobe, which is abResults
Clinical data
Data for 32 patients are shown in Table 1. All patients were
from China. The images from CT and cystoscopic views revealed
that all 32 patients suffered from muscle-invasive bladder cancer
(clinical staging T2-T4aN0M0). There were 22 males and 10
females and their age ranged from 52 to 79 years. The mean tumor
size on preoperative CT was 2.8 cm (range, 1.3–4.7) and there was
no signiﬁcant difference from the intraoperative measurement of
2.9 cm (range, 1.3–4.4). There has been some evidence to suggest
that the cryoablation protocol is most efﬁcacious for a tumor size
of less than 4.0 cm [17]. Following the growth of our clinical expe-
rience, we were able to treat larger masses (tumor size did not
exceed 5 cm). Therefore, in our study, the size of the tumors trea-
ted with cryoablation ranged from 1.3 to 4.7 cm.
Perioperative outcomes
Argon–helium cryoablation was successfully performed in all
32 patients. All tumors were completely ablated with a single pro-
cedure of cryoablation, except for two tumors that were ablated
with two sessions of treatment. The ﬁrst patient enrolled in the
trial had small residual enhanced nodules at the periphery of the
lesion, and the cyst was detected at 24 h after the cryoablation pro-
cedure. The patient’s tumor, a 1.8 cm bladder cancer, showed
residual enhancement in the portion that abutted the treated site
and the patients was retreated by cryoablation. The other patient
suffered a recurrence 6 months after cryoablation therapy. This
patient initially had a 2.3 cm tumor mass, and was suspected to
have a small residual hubble according to the image ﬁndings of
the 3-month follow-up CT scan. Enhancement of the residual hub-
ble was conﬁrmed at the 6-month CT scan, and was retreated by
cryoablation at 9 months after the initial treatment. Subsequently,
CT images obtained for this patient at 3 and 6 months after the sec-
ond treatment did not show any evidence of another recurrence.
For small tumors, a single cryoprobe was used to ablate the tumor,
whereas multiple cryoprobes were used to ablate the largeration system (Cryo-hit, Galil Medical, Israel; employing argon/helium gases using
le to form a 3.0  5.0 cm iceball.
Table 2
Clinical ﬁndings of 32 bladder cryoablation patients treated on protocol.
Symptoms Before cryosurgery,
no. of patients (%)
After cryosurgery,
no. of patients (%)
P value
Hematuria 20 (62.5) 11 (34.4) <0.05
Urinary irritation 5 (15.6) 2 (6.3) <0.05
Abdominal pain 10 (31.3) 5 (15.6) <0.05
Lumbago 4 (12.5) 1 (3.1) <0.05
L. Sun et al. / Cryobiology 69 (2014) 318–322 321tumors. CT performed within 24 h after treatment showed that all
tumors were completely ablated. A total of 29 of 32 patients had
33-month follow-up (range, 6–48 months) data that was adequate
for analysis. The results indicated that there was no tumor recur-
rence or enhancement, except for the above two cases. Examples
of the CT scans for the patients are shown in Fig. 2. Complete res-
olution of the treated mass or a residual small cyst without
enhancement was observed in CT for all patients during the fol-
low-up period (Fig 3), except for three patients who were lost to
follow-up. There was no signiﬁcant complications but no major
complications associated with the cryoablation procedure. Symp-
toms of bladder cancer present before and within 3 days after per-
cutaneous cryoablation are shown in Table 2. All complications had
disappeared completely after 2 weeks.
Discussion
Radical cystectomy and transurethral resection are currently
the reference standards for treating muscle-invasive bladder can-
cer [6,22]. A high recurrence rate is one of the main characteristicsFig. 2. Computed tomography (CT) imaging-guided percutaneous cryotherapy of muscle-
soft tissue mass (arrow) on the left posterior side of the bladder wall. (B) The intraoperati
tissues and the position of the iceball formed. (C) The postoperative CT scan shows that
Fig. 3. Follow-up computed tomography (CT) imaging of muscle-invasive bladder cancer
recurrence. The partial bladder wall is smooth. (A) CT image 8 months after cryothera
intravenous injection of iodine contrast agent. (B) CT image at 3 months after cryoablatio
(D) CT image at 12 months after cryoablation of bladder cancer.of transurethral resection, with some evidence to suggest a 76%
repeated procedure rate at the original tumor site after transure-
thral resection [2]. Radical cystectomy is recommended as a cura-
tive treatment for advanced bladder cancer; however, more than
half of these patients show distant metastasis as the predominant
form of disease recurrence [11]. Although these therapeutic meth-
ods have achieved some positive effects, therapies for bladder can-
cer are far from satisfactory.
Argon–helium cryoablation, a new local ablative modality for
the treatment of tumors, has been applied to various tumors,invasive bladder cancer in a 76-year-old man. (A) The preoperative CT scan shows a
ve CT scan shows a single cryoprobe (arrow) inserted into the tumor within the soft
the tumor was completely ablated.
in a 76-year-old man. There is no evidence to suggest enhancement of the tumor or
py. (B–D) CT images of patients with bladder cancer taken at various times after
n of bladder cancer. (C) CT image at 6 months after cryoablation of bladder cancer.
322 L. Sun et al. / Cryobiology 69 (2014) 318–322including hepatocellular carcinoma, renal carcinoma, prostate
cancer, etc. There is a substantial body of evidence showing that
percutaneous cryoablation treatment is very effective. In several
studies, the local control rates of the treatment reached 83–95%
on the basis of short-term follow-up [21]. In recent years, our
group has successfully carried out percutaneous cryoablation
treatment for different kinds of tumors, such as hepatocellular car-
cinoma, renal carcinoma, prostate cancer, renal angiomyolipoma,
lung carcinoma, pelvic neoplasms, pancreatic carcinoma, adrenal
neoplasm, and sacrum and ilium tumors. In the present study,
our aim was to evaluate the efﬁcacy and safety of CT imaging-
guided percutaneous argon–helium cryoablation of muscle-inva-
sive bladder cancer. Thus, we performed local tumor cryoablation
for 32 patients with muscle-invasive bladder cancer on the condi-
tion that the patients accepted the treatment. Our present data
suggest that CT imaging-guided percutaneous argon–helium cryo-
ablation of muscle-invasive bladder cancer is a successful tech-
nique. Follow-up CT was used as a measure of success by
comparing this with the control images. Tumors in all 32 patients
enrolled in the trial were ablated successfully by a single session,
except the ﬁrst two patients who received two sessions of
cryoablation.
Follow-up data indicated that all patients’ tumors were com-
pletely resolved without enhancement, as observed by CT during
the short-term imaging follow-up period, except for three patients
who were lost to follow-up. Our previous results have suggested
that most residual mass is detected in the early stage after ablation,
typically within 3 months of cryoablation. This ﬁnding is consis-
tent with the observation of a prior study, which showed that
70% of tumor recurrence is detected within 3 months [12]. Evi-
dence shows that the incidence of recurrent tumor beyond
3 months is low, occurring at a rate of only 1% [1]. Thus, our
short-term imaging follow-up data could indicate that all patients
in our study were cured. Potential complications of bladder cryo-
surgery include post-thaw hemorrhage, vesical ﬁstula formation,
and uroclepsia. Vesical ﬁstula and uroclepsia did not occur in any
patient in our study, as conﬁrmed by CT scanning. There was some
evidence to suggest that bleeding from the probe tract was limited
by using small probes, which are available with this argon gas-
based system [10]. 1.47 mm cryoprobes were used for our study,
and there was no signiﬁcant bleeding in all patients but one, and
the median blood loss of patients after treatment was approxi-
mately 185 mL. The hematocrit level of one patient was signiﬁ-
cantly reduced. They received a blood transfusion after the
cryoablation treatment and their hematocrit level had returned
to the baseline level after 1 week.Conclusion
In our study, we have described our experience with a mini-
mally invasive method for ablating bladder tumors for the ﬁrst
time. We have demonstrated that CT imaging-guided percutaneous
cryotherapy is a very effective and safe technique for treating
bladder cancer. CT imaging can be used to monitor preoperative,
intraoperative, and postoperative tumors of patients, and to ensure
that the tumor is completely ablated. Notably, this procedure can
be accomplished with local anesthesia. Although percutaneous
argon–helium cryoablation requires further assessment, the
method shows promise.References
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